Fundz Deep Dive

Everything you need to win J. Michael Edwards — in one platform.

Who to reach, what to say, and why now on J. Michael Edwards — plus every funding round, exec hire, and M&A move that follows, each with the verified contact and the outreach written for you.

Get the full Deep Dive on J. Michael Edwards — free.

One free Deep Dive, emailed to you. No spam; unsubscribe anytime.

Ready now? Choose your plan · Request a demo · Sign in

Engage writes the reply

Grounded in signals no one else has — tuned to their persona.

Signals no one else has

UCC liens, benefit plans, 13F holdings, permits, exec moves — fused.

Verified contact + click-to-call

The decision-maker’s email and mobile — dial in-browser.

Bio Affinity Technologies Appoints J. Michael Edwards As Chief Financial Officer (CFO)

PUBLIC · BIAFOct 10, 2024•over 1 year ago

Position

Chief Financial Officer

Company

bioAffinity Technologies

J. Michael Edwards

San AntonioBiotechnologyHealth CareTherapeuticsHealth Diagnostics

Description

bioAffinity Technologies, Inc. announced the appointment of J. Michael Edwards as Chief Financial Officer (CFO), who will report directly to President and CEO Maria Zannes

Company Information

Company

bioAffinity Technologies

Location

San Antonio, Texas, United States

About

bioAffinity Technologies, Inc. (NASDAQ: BIAF, BIAFW) addresses the need for noninvasive diagnosis of early-stage cancer and diseases of the lung, and targeted cancer treatment. The Company’s first product, CyPath® Lung, is a non-invasive test that has shown high sensitivity and specificity for the detection of early-stage lung cancer. CyPath® Lung is marketed as a Laboratory Developed Test (LDT) by Precision Pathology Services. OncoSelect® Therapeutics, LLC, a subsidiary of bioAffinity Technologies, is advancing its discoveries shown in vitro to kill cancer cells without harm to normal cells. Research and optimization of the Company’s platform technologies are conducted in its laboratories at The University of Texas at San Antonio.

Related People

Suggested for you

Choose your plan to reveal verified contacts

Predictive Intelligence

Strategic

ML-powered predictions for bioAffinity Technologies's next move

Learn about Strategic plan

Executive Insights

Based on hiring data

New executive impact window

87% of new executives make significant technology decisions within first 100 days

Budget influence

C-level executives control 73% of technology spending decisions

Transformation catalyst

65% of new senior hires launch digital transformation initiatives

Vendor review timeline

New executives typically review existing vendors within 6 months